49.22
+1.555(+3.26%)
Currency In USD
| Previous Close | 47.67 |
| Open | 47.89 |
| Day High | 49.81 |
| Day Low | 45.52 |
| 52-Week High | 54.3 |
| 52-Week Low | 3.65 |
| Volume | 22,203 |
| Average Volume | 42,888 |
| Market Cap | 303.69M |
| PE | -12.82 |
| EPS | -3.84 |
| Moving Average 50 Days | 39.37 |
| Moving Average 200 Days | 35.32 |
| Change | 1.56 |
If you invested $1000 in Monopar Therapeutics Inc. (MNPR) since IPO date, it would be worth $371.47 as of September 13, 2025 at a share price of $49.22. Whereas If you bought $1000 worth of Monopar Therapeutics Inc. (MNPR) shares 5 years ago, it would be worth $1,802.93 as of September 13, 2025 at a share price of $49.22.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting
GlobeNewswire Inc.
Sep 03, 2025 12:00 PM GMT
WILMETTE, Ill., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs,
Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments
GlobeNewswire Inc.
Aug 12, 2025 12:00 PM GMT
WILMETTE, Ill., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, t
Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers
GlobeNewswire Inc.
Jun 11, 2025 11:00 AM GMT
WILMETTE, Ill. and HOUSTON, Texas, June 11, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar,” the “Company,” “us” and “our”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for pat